Temozolomide and Other Alkylating Agents in Glioblastoma TherapyHannah A. Strobel, Mike‐Andrew WesthoffBiomedicinesSeptember 9, 201910.3390/biomedicines7030069Cited by 276SaveCiteExport RISWatch citationsRelated PapersInhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells|International Journal of Oncology|2018|15